RHYTHM PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 11.83 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 11.83M shares, a 9.06% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 12.18M shares, a 7.98% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 12.80M shares, a 6.98% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 13.01M shares, a 6.57% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 12.41M shares, a 5.22% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 11.79M shares, a 43.59% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.21M shares, a 3.51% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.93M shares, a 11.28% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 11.83M shares 10-Q · filed 2026-08-04 | 11.83M shares 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | 12.18M shares 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 12.41M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 12.80M shares 10-Q · filed 2025-11-04 | 12.80M shares 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 13.01M shares 10-Q · filed 2026-08-04 | 13.01M shares 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | 13.24M shares 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | 11.79M shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 11.97M shares 10-Q · filed 2025-11-04 | 11.97M shares 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | 12.21M shares 10-Q · filed 2025-08-05 | 12.21M shares 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | 8.80M shares 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 8.21M shares 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 8.55M shares 10-Q · filed 2024-11-06 | 8.55M shares 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 8.72M shares 10-Q · filed 2024-08-06 | 8.72M shares 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | 8.63M shares 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 7.93M shares 10-K · filed 2025-02-28 | |||
| 2022-09-30 | 8.12M shares 10-Q · filed 2023-11-08 | 8.12M shares 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | 8.74M shares 10-Q · filed 2023-08-01 | 8.74M shares 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | 8.97M shares 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | 7.13M shares 10-K · filed 2024-02-29 | |||
| 2021-09-30 | 6.41M shares 10-Q · filed 2022-11-08 | 6.41M shares 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | 5.34M shares 10-Q · filed 2022-08-03 | 4.82M shares 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | 3.74M shares 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | 5.38M shares 10-K · filed 2023-03-01 | |||
| 2020-09-30 | 5.28M shares 10-Q · filed 2021-11-02 | 5.28M shares 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | 4.44M shares 10-Q · filed 2021-08-03 | 4.44M shares 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | 4.18M shares 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | 3.43M shares 10-K · filed 2022-03-01 | |||
| 2019-09-30 | 3.59M shares 10-Q · filed 2020-11-02 | |||
| 2019-06-30 | 3.70M shares 10-Q · filed 2020-08-03 | |||
| 2019-03-31 | 3.71M shares 10-Q · filed 2020-05-04 | |||
| 2018-12-31 | 2.62M shares 10-K · filed 2021-03-01 | |||
| 2018-09-30 | 2.47M shares 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | 2.62M shares 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | 2.43M shares 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | 1.83M shares 10-K · filed 2020-03-02 | |||
| 2017-09-30 | 10.65M shares 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | 8.03M shares 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | 7.63M shares 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |